Skye Bioscience 2024 Endocannabinoid System Investor Presentation

Skye Bioscience outlines its strategy to develop novel pharmaceutical products targeting the endocannabinoid system, with focus on CB1 receptor modulation. The presentation covers clinical development of product candidates including nimacimab and SBI-100 Ophthalmic Emulsion, addressing neuropathic, inflammatory, and metabolic diseases.